Document is current
Any future updates will be listed below
-
Authors
Behr, Juergen
Bonella, Francesco
Günther, Andreas
Koschel, Dirk
Prasse, Antje
Pittrow, David
Klotsche, Jens
Kreuter, Michael
,
Andreica, Ioana
Behr, Jürgen
Biller, Heike
Claussen, Martin
Budweiser, Stephan
Eisenmann, Stephan
Ewert, Ralf
Gesierich, Wolfgang
Gläser, Sven
Grohé, Christian
Grund, Daniel
Grünewaldt, Achim
Hagmeyer, Lars
Held, Matthias
Kabitz, Hans-Joachim
Kirschner, Joachim
Markart, Philipp
Neff, Ulrich
Neurohr, Claus
Reichenberger, Frank
Schramm, Peter
Schwaiblmair, Martin
Seese, Bernd
Skowasch, Dirk
Wälscher, Julia
Weber, Michael
Westhoff, Michael
Wilkens, Heinrike
Wirtz, Hubert
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
Universitätsklinik München
- License Information
-
More Information
Article History
Received: 1 September 2022
Accepted: 18 January 2023
First Online: 11 February 2023
Declarations
:
: The registry materials (protocol, patient information and informed consent form (ICF), and other required documents) were approved by the primary ethics committee (Ethics Committee of the Physician Chamber Saxony EK-BR-125/21-1 dated 1. December 2021). Any site that joins the registry has to provide additional ethics approval, if required by their local institutions. Protocol amendments, if any, will be subject to the same requirements as the original protocol. Written informed consent is a prerequisite for patients to be eligible for documentation in the study.
: Not applicable. The manuscript does not contain any individual person’s data in any form.
: JB: Jürgen Behr received honoraria for consulting and lectures from Actelion, Astra-Zeneca, Biogen, BMS, Boehringer-Ingelheim, Ferrer, Galapagos, Novartis, Roche, Sanofi-Genzyme. The INSIGHTS-ILD study is funded by Boehringer Ingelheim, Germany. FB: grants to his institution by Boehringer Ingelheim and Roche, fees for consulting by Savara, Roche, Sanofi and Boehringer Ingelheim. DP: received consultancy fees from Amgen, Aspen, Biogen, Daiichi Sankyo, Sanofi-Genzyme, Sandoz/Novartis and MSD. AP: none. JK: none. DK: fees for consulting by Roche and Boehringer Ingelheim. MK: grants to his institution by Boehringer Ingelheim and Roche, fees for consulting by Roche, Galapagos and Boehringer Ingelheim.
